Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2005 1
2012 1
2013 1
2015 5
2016 6
2017 4
2018 8
2019 9
2020 11
2021 10
2022 18
2023 60
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Mismatch repair cancer syndrome 3"
Page 1
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Le DT, et al. Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8. Science. 2017. PMID: 28596308 Free PMC article. Clinical Trial.
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Bendell J, Le DT, Yoshino T, Van Cutsem E, Yang P, Farooqui MZH, Marinello P, Diaz LA Jr; KEYNOTE-177 Investigators. André T, et al. N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699. N Engl J Med. 2020. PMID: 33264544 Free article. Clinical Trial.
BACKGROUND: Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 blockade as compared with chemotherapy as first-line therapy for MSI-H-dMM …
BACKGROUND: Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability-high (MSI-H) or mismatch-repair-def …
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J, Svrcek M, Cohen R, Basile D, Tougeron D, Phelip JM. Taieb J, et al. Eur J Cancer. 2022 Nov;175:136-157. doi: 10.1016/j.ejca.2022.07.020. Epub 2022 Sep 14. Eur J Cancer. 2022. PMID: 36115290 Review.
In both cases (metastatic and non-metastatic settings) treatment with immune check-point inhibitors (ICIs) have shown a remarkable effectiveness in the context of MSI/dMMR status. Indeed, recent data from prospective cohorts and randomised trials have shown a dramatical im …
In both cases (metastatic and non-metastatic settings) treatment with immune check-point inhibitors (ICIs) have shown a remarkable effective …
Immunotherapy, Inflammation and Colorectal Cancer.
Lichtenstern CR, Ngu RK, Shalapour S, Karin M. Lichtenstern CR, et al. Cells. 2020 Mar 4;9(3):618. doi: 10.3390/cells9030618. Cells. 2020. PMID: 32143413 Free PMC article. Review.
In recent years, however, combinational treatment with targeted therapies, such as vascular endothelial growth factor, or epidermal growth factor receptor inhibitors, has proven to be quite effective in patients with specific CRC subtypes. While scientific and clinical adv …
In recent years, however, combinational treatment with targeted therapies, such as vascular endothelial growth factor, or epidermal growth f …
Treatment options for molecular subtypes of endometrial cancer in 2023.
Karpel HC, Slomovitz B, Coleman RL, Pothuri B. Karpel HC, et al. Curr Opin Obstet Gynecol. 2023 Jun 1;35(3):270-278. doi: 10.1097/GCO.0000000000000855. Epub 2023 Mar 20. Curr Opin Obstet Gynecol. 2023. PMID: 36943683 Review.
SUMMARY: Molecular subtyping has important prognostic and therapeutic implications and should be guiding patient management and clinical trial design in endometrial cancer....
SUMMARY: Molecular subtyping has important prognostic and therapeutic implications and should be guiding patient management and clinical …
Biomarker-driven therapy in endometrial cancer.
Karpel H, Slomovitz B, Coleman RL, Pothuri B. Karpel H, et al. Int J Gynecol Cancer. 2023 Mar 6;33(3):343-350. doi: 10.1136/ijgc-2022-003676. Int J Gynecol Cancer. 2023. PMID: 36878569 Review.
Molecular subtyping has important prognostic and therapeutic implications, and should guide patient management and clinical trial design in endometrial cancer, which is a molecularly driven disease....
Molecular subtyping has important prognostic and therapeutic implications, and should guide patient management and clinical trial …
Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H, He X, Wang Q. Peng H, et al. Acta Obstet Gynecol Scand. 2022 Sep;101(9):941-951. doi: 10.1111/aogs.14412. Epub 2022 Jun 25. Acta Obstet Gynecol Scand. 2022. PMID: 35751489 Free PMC article. Review.
All clinical trials of ICB therapy in gynecological cancers were reviewed. ...Six phase III clinical trials have reported their results of primary outcomes, and a total of 25 phase II clinical trials have been completed. ...
All clinical trials of ICB therapy in gynecological cancers were reviewed. ...Six phase III clinical trials have reported thei …
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects.
de Vries NL, van de Haar J, Veninga V, Chalabi M, Ijsselsteijn ME, van der Ploeg M, van den Bulk J, Ruano D, van den Berg JG, Haanen JB, Zeverijn LJ, Geurts BS, de Wit GF, Battaglia TW, Gelderblom H, Verheul HMW, Schumacher TN, Wessels LFA, Koning F, de Miranda NFCC, Voest EE. de Vries NL, et al. Nature. 2023 Jan;613(7945):743-750. doi: 10.1038/s41586-022-05593-1. Epub 2023 Jan 11. Nature. 2023. PMID: 36631610 Free PMC article.
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. Baxter NN, et al. J Clin Oncol. 2022 Mar 10;40(8):892-910. doi: 10.1200/JCO.21.02538. Epub 2021 Dec 22. J Clin Oncol. 2022. PMID: 34936379
METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical practice. RESULTS: Twenty-one observational studies and six randomized controlled trials met the systematic review inclusion criteria. …
METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studies and develop recommendations for clinical pr …
Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti-PD-1 Immunotherapy in Endometrial Carcinoma.
Chow RD, Michaels T, Bellone S, Hartwich TMP, Bonazzoli E, Iwasaki A, Song E, Santin AD. Chow RD, et al. Cancer Discov. 2023 Feb 6;13(2):312-331. doi: 10.1158/2159-8290.CD-22-0686. Cancer Discov. 2023. PMID: 36301137 Free PMC article.
Mismatch repair-deficient (MMRd) cancers have varied responses to immune-checkpoint blockade (ICB). We conducted a phase II clinical trial of the PD-1 inhibitor pembrolizumab in 24 patients with MMRd endometrial cancer (NCT02899793). ...Tumors with epigenetic MMRd o …
Mismatch repair-deficient (MMRd) cancers have varied responses to immune-checkpoint blockade (ICB). We conducted a phase II clinical …
129 results